Hospital Universitari De Girona Doctor Josep Trueta
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Stroke
At Hospital Universitari De Girona Doctor Josep Trueta, research in cardiovascular diseases focuses on stroke, myocardial protection, and heart failure prevention. These trials are testing new treatments and strategies to reduce damage after acute events, improve recovery, and lower the risk of future cardiovascular complications.
- Acute ischemic stroke and prevention of recurrent stroke
- Tranexamic acid and other therapies for intracerebral hemorrhage
- Cardiovascular risk reduction in obesity and related conditions
- Therapies for genetic dilated cardiomyopathy and ventricular function preservation
The site is contributing to studies that aim to improve emergency care, support long-term prevention, and evaluate whether newer approaches can make cardiovascular treatment more effective and safer.
Oncology and Urologic Cancers
Clinical research in neoplasms covers several major cancers, including prostate cancer, breast cancer, endometrial cancer, bladder cancer, renal cancer, and lung cancer. The trials are mainly designed to test new cancer therapies, compare treatment combinations, and improve outcomes after surgery or during advanced disease.
- Advanced and early-stage breast cancer
- Metastatic and castration-resistant prostate cancer
- Endometrial, bladder, and renal cancers
- Non-small cell lung cancer and other solid tumors
This oncology portfolio reflects a strong focus on evaluating treatment effectiveness, extending survival, and helping define better options for patients with hard-to-treat cancers.
Neurology and Cerebrovascular Research
The site also supports studies in nervous system diseases, especially multiple sclerosis and acute brain injury. Research here is centered on improving stroke care, testing therapies that may protect brain tissue, and assessing longer-term safety and benefit in chronic neurological disorders.
- Acute stroke treatment and clot-related brain injury
- Prevention of ischemic stroke after transient ischemic attack
- Long-term therapy for relapsing and progressive multiple sclerosis
- Evaluation of emergency and hospital-based neuroprotective approaches
These trials are aimed at better recovery, fewer complications, and more reliable treatment options for patients with urgent and chronic neurological conditions.
Digestive System Diseases
In digestive system diseases, the research includes Crohn's disease and ulcerative colitis. The studies are focused on improving symptom control, supporting remission, and finding more effective maintenance treatments for people living with inflammatory bowel disease.
- Clinical remission in ulcerative colitis
- Maintenance treatment for Crohn's disease
- Long-term safety and effectiveness of inflammatory bowel disease therapies
This work helps evaluate whether newer medicines can provide better disease control and a more durable response over time.
Respiratory, Infectious, and Vaccine Research
The site’s activity in respiratory tract diseases and virus diseases includes studies in pneumonia, bronchiectasis, SARS-CoV-2 infection, and influenza. Research here is aimed at testing treatments for serious lung infections and assessing vaccine safety, tolerability, and immune response in different age groups.
- Severe community-acquired pneumonia and other serious respiratory infections
- Chronic Pseudomonas aeruginosa infection in bronchiectasis
- COVID-19 and influenza vaccine studies
- Therapies targeting infectious burden and immune protection
These trials support both treatment development and prevention, with an emphasis on reducing infection-related complications and strengthening public health protection.
Metabolic and Reproductive Health
Research in nutritional and metabolic diseases and reproductive and urinary physiological phenomena includes studies on obesity and contraceptive efficacy. The goal is to evaluate whether new approaches can improve cardiovascular safety in excess weight and offer reliable options for pregnancy prevention.
- Cardiovascular safety in people with overweight or obesity
- Evaluation of contraceptive effectiveness and tolerability
This area combines prevention-focused research with practical questions relevant to everyday health and long-term wellbeing.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 24 therapeutic areas and 15 of 238 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 223 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 47 by active trials.
lock +46 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitari De Girona Doctor Josep Trueta
lock Showing 1 of 121 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 238 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 10 | Unknown | 2017-06-08 | 2026-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
